Results from a phase II trial of a combination of lenvatinib plus pembrolizumab for the treatment of metastatic renal cell carcinoma (RCC) which was not responding to treatment with immune checkpoint inhibitor therapy was presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend. One hundred and four (104) patients […]
A paper presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend showed that histologic subtypes of metastatic renal cell carcinoma (RCC) differ in the location of their metastases. For example, lung, adrenal, brain, and pancreatic metastases occur more frequently with clear cell RCC than with papillary RCC or chromophobe […]
A recent retrospective study looked at the data from 49 patients with metastatic papillary renal cell carcinoma (RCC) who were taking targeted therapy (VEGF-TKIs). The study showed that patients on targeted therapy and with bone metastases from papillary RCC have worse progression-free survival and overall survival than patients without bone metastasis. Patients with papillary RCC […]
There are a number of immune checkpoint inhibitor drugs available for the treatment of people with metastatic renal cell carcinoma (RCC), but the efficacy and safety of treating patients with two separate lines of immunotherapy (rechallenge) is unknown. This study looked at the safety and efficacy of rechallenge with an immune checkpoint inhibitor in patients […]
This article gives a good, easy-to-understand summary of how the different types of immunotherapy work to treat advanced kidney cancer: How immunotherapy can treat advanced kidney cancer
Results from the phase II FRACTION-RCC clinical trial to assess the nivolumab plus ipilimumab combination in previously treated advanced renal cell carcinoma (RCC) patients were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend. The study looked at 46 patients with previously treated RCC that was not responding to […]
Results from a phase II study of bevacizumab and erlotinib in people with advanced hereditary leiomyomatosis and papillary renal cell cancer (HLRCC) or sporadic papillary RCC were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend. This study included 83 patients with papillary RCC. Half of the patients […]
Two studies were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to investigate whether initial treatment of metastatic renal cell carcinoma (RCC) patients with nivolumab followed by the addition of ipilimumab for patients with either stable or progressive disease would be as effective as upfront combination therapy and with less side […]
Biomarkers enable doctors predict which patients will respond to which drugs, and have an important role in many cancers. However, a good biomarker has not yet been found for renal cell carcinoma (RCC). The fundamental issue in the biology of metastatic RCC is that a suitable genetic mutation that ‘drives’ the development of RCC has […]
Results from a phase II international trial led by researchers at MD Anderson Cancer Center in America were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial showed treatment with a novel hypoxia inducible factor (HIF)-2 alpha inhibitor (MK-6482) was well tolerated and resulted in clinical responses in patients with von […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
